Pharvaris' oral hereditary angioedema med slashes attacks in turnaround post-FDA hold

Patients taking Pharvaris’ preventative oral medicine for hereditary angioedema experienced an 84.5% reduction in monthly attacks during a phase 2 study. The results represent a turnaround for the medicine, which until June was on a clinical hold by the FDA.